Effect of Buffers and Stabilizers on Vaccine Stability and Efficacy

Development of Vaccines: From Discovery to Clinical Testing

Volumn , Issue , 2011, Pages 399-410

  Apte, Shireesh P ^a   Ugwu, Sydney O ^b  

^a Pfizer Vaccine Research ^*

^b Pfizervaccine Research   (United States)

Author keywords

Buffer and stabilizer effect on vaccine stability and efficacy; Excipient effect on vaccine efficacy buffer effects, on protein conformational stability; Polymeric zwitterionic (ZPS) buffers CD4+ T cell responses, positively and negatively charged

Indexed keywords

EID: 84886138088     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118023648.ch15     Document Type: Chapter

References (69)

1. Kreilgaard L, Jones L, Randolph TW, Frokjaer S, Flink J, Manning MC, and Carpenter JF. Effects of Tween-80 on agitation- and freeze-thawing-induced aggregation of recombinant Factor XIII. J. Pharm. Sci . 1998;87:1597.
2. Dickersen E. Adsorbed protein layers at fluid interfaces: Interactions, structure and surface rheology. Colloids Surfaces B: Biointerfaces 1999;15:161-176.
3. Peek LJ, Brandau DT, Jones LS, Joshi SB, and Middaugh R. A systematic approach to stabilizing EBA-175 RII-NG for use as malaria vaccine. Vaccine 2006;24:5839-5851.
4. Singh S, Singh A, Aziz MA, Waheed SM, Bhat R, and Bhatnagar R. Thermal inactivation of protective antigen of Bacillus anthracis and its prevention by polyol osmolytes. Biochem. Biophys. Res. Commun. 2004;322:1029-1037.
5. Sarkar J, Sreenivasa BP, Singh P, Dhar P, and Bandyopadhyay SK. Comparative efficacy of various chemical stabilizers on the thermostability of live-attenuated peste des petits ruminants (PPR) vaccine. Vaccine 2003;21:4728-4735.
6. Wakankar AA and Borchardt RT. Formulation considerations for proteins susceptible to asparagine deamidation and aspartate isomerization. J. Pharm. Sci . 2006;95:2321-2336.
7. Geiger T and Clarke S. Deamidation, isomerization and racemization at asparaginyl and aspartyl residues in peptides. Succinimide-linked reactions contribute to protein degradation. J. Biol. Chem. 1987;262:785-794.
8. Zomber G, Reuvenys S, Garti N, Shafferman A, and Elhanany E. Effects of deamidation on cytotoxi activity of bacillus anthracis protective antigen. J. Biol. Chem.280:39897-39906.
9. Parkins DA and Lashmar UT. The formulation of biopharmaceutical products. PSTT 2000;3:129-137.
10. Li S, Schoneich C, and Borchardt RT. Chemical instability of protein pharmaceuticals: Mechanisms of oxidation and strategies for stabilization. Biotechnol. Bioeng. 1995;48:490-500.
11. Evans RK, Nawrocki DK, Isopi LA, Williams DM, Casimiro DR, Chin S, Chen M, Zhu D-M, Shiver JW, and Volkin DB. Development of stable liquid formulations for adenovirusbased vaccines. J. Pharm. Sci . 2004;93(10):2458-2475.
12. Verheyden B, Andries K, and Rombaut B. Capsid and RNA stabilization of the oral polio vaccine. Vaccine 2001;19:1899-1905.
13. Tsang SK, Danthi P, Chow M, and Hogle JM. Stabilization of poliovirus by capsid-binding antiviral drugs is due to entropic effects. J. Mol. Biol . 2000;296:335-340.
14. Melnick JL and Wallis C. Effect of pH on thermal stabilization of oral poliovaccine by magnesium chloride. Proc. Soc. Exp. Biol. Med. 1963;112:894-897.
15. Wallis C and Melnick JL. Cationic stabililzation-a new property of enteroviruses. Virology 1962;16:504-506.
16. Bovamick MA, Miller JC, and Snyder JC. The influence of certain salts, amino acids, sugars and proteins on the stability of rickettsiae. J. Bacteriol . 1950;59:509-522.
17. Rombaut B, Verheyden B, Andries K, and Boeye A. Thermal inactivation of oral polio vaccine: Contribution of RNA and protein inactivation. J. Virol . 1994;68:6454-6457.
18. Reiff D, Rightsel WA, and Schuler EE. Effects of freezing, storage at low temperature, and drying by sublimation in vacuo on the activities of measles. Nature 1964;202:624-625.
19. Amorij J-P, Meulenaar J, Hinrichs WLJ, Stegmann T, Huckriede A, Coenen F, and Frijlink HW. Rational design of an influenze subunit powder with sugar glass technology: Preventing conformational changes of haemagglutinin during freezing and freeze-drying. Vaccine 2007;25:6447-6457.
20. Patist A and Zoerb H. Preservation mechanisms of trehalose in food and biosystems. Colloids Surfaces B: Biointerfaces 2005;40:107-113.
21. Mohammed AR, Bramwell VW, Coombes AGA, and Perrie, Y. Lyophilization and sterilization of liposomal vaccines to produce stable and sterile products. Methods 2006;40:30-38.
22. de Jonge J, Amorij J-P, Hinrichs WLJ, Wilschut J, Huckriede A, and Frijlink HW. Inulin sugar glasses preserve the structural integrity and biological activity of influenze virosomes during freeze-drying and storage. Eur. J. Pharm. Sci . 2007;32:33-44.
23. Francon, AK and Montagnon BJ. Stabilizing vaccines. U.S. Patent No. 5075110, 1991.
24. Loudon, PT and Varley, CA. Stabilization of herpes virus preparations. U.S. Patent No. 6258362, 2001.
25. Singh S, Aziz MA, Khandelwal P, Bhat R, and Bhatnzgar R. The osmoprotectants glycine and its methyl derivatives prevent the thermal inactivation of protective antigen of Bacillus anthracis. 2004;316:559-564.
26. Wu R, Georgescu M-M, Delpeyroux G, Guillot S, Balanant J, Simpson K, and Crainic R. Thermostabilization of of live virus vaccines by heavy water (D20). Vaccine 1995;13:1058-1063.
27. Bouvier A, Chapline J, Boerner R, Jeyarajah S, Cook S, Acharya PS, Henderson I, Schrimsher L, and Shepard, Sr. Identifying and modulating disulfide formation in the biopharmaceutical production of a recombinant protein vaccine candidate. J. Biotechnol. 2003;103:257-271.
28. Chen P-L, Wang M, Ou W-C, Lii C-K, Chen L-S, and Chang D. Disulfide bonds stabilize JC virus capsid-like structure by protecting calcium ions from chelation. FEBS Lett . 2001;500:109-113.
29. Emslie, KR, Coukell, MB, Birch D, and Williams KL. Calcium influences the stability and conformation of rotavirus SA11 glycoprotein VP7 expressed in Dixtyostelium discoideum. J. Biotechnol. 1996;50:149-159.
30. Francki RIB and Habili N. Stabilization of capsid structure and enhancement of immunogenicity of cucumber mosaic virus (Q strain) by formaldehyde. Virology 1972;48: 309-315.
31. Rappuoli R. Toxin inactivation and antigen stabilization: Two different uses of formaldehyde. Vaccine 1994;12:579-581.
32. Ugwu SO and Apte SP. The effect of buffers on protein conformational stability. Pharm. Tech. 2004:86-113.
33. Streicher HZ, Berkower IJ, Busch M, Gurd FR, and Berzofsky JA. Antigen conformation determines processing requirements for T-cell activation. Proc. Natl. Acad. Sci. USA. 1984;81(21):6831-6835.
34. Thai R, Moine G, Desmadril M, Servent D, Tarride J-L, Menez A, and Leonetti M. Antigen stability controls antigen presentation. J. Biol. Chem. 2004;279(48):50257-50266.
35. Carra JH, Wannemacher RW, Tammariello RF, Lindsey CY, Dinterman RE, Schokman RD, and Smith LA. Improved formulation of a recombinant ricin A chain vaccine increases its stability and effective antigenicity. Vaccine 2007;25:4149-4158.
36. Jones LS, Peek LJ, Power J, Markham A, Yazzie B, and Middaugh CR. Effects of adsorption to aluminum salt adjuvants on the structure and stability of protein antigens. J. Biol. Chem. 2005;280(14):13406-13414.
37. Peterson SE, Wang S, Ranheim T, and Owen KE. Citrate mediated disaggregation of rotavirus particles in Rotateq vaccine. Antiviral Res. 2006;69:107-115.
38. Phelps DK and Post CB. A novel basis for capsid stabilization by antiviral compounds. J. Mol. Biol . 1995;254:544-551.
39. Pattenden LK, et.al. Towards the preparative and large scale precision manufacture of virus like particles. Trends Biotechnol. 2005;23(10):523-529.
40. Wittayanukulluk A, Jiang D, Regnier FE, and Hem SL. Effect of microenvironment pH of aluminum hydroxide adjuvant on the chemical stability of adsorbed antigen. Vaccine 2004;22:1172-1176.
41. Sack DA, Shimko J, Sack RB, Gomes JG, MacLeod K, O'Sullivan D, and Spriggs D. Comparison of alternative buffers for use with a new live oral Cholera vaccine, Peru-15 in outpatient volunteers. Infect. Immun. 1997;65(6):2107-2111.
42. Ferruti P, Manzoni S, Richardson SCW, Pattrick NG, Mendichi R, and Casolaro M. Amphoteric linear poly(amido-amine)s as endosomolytic polymers: Correlation between physicochemical and biological properties. Macromolecules 2000;33:7793-7800.
43. Yang Z, Zhu J, Sriadibhatla S, Gebhart C, Alakhov V, and Kabanov A. Promoter and strain selective enhancement of gene expression in a mouse skeletal muscle by a polymer excipient Pluronic P85. J. Control. Release 2005;108:496-512.
44. Rao RJ, Tiwari AK, Kumar US, Reddy SV, Ali AZ, and Rao JM. Novel 3-O-Acyl Mesquitol analogues as free radical scavengers and enzyme inhibitors: synthesis, biological evaluation and structure-activity relationship. Bioorg. Med. Chem. Lett . 2003;13:2777-2780.
45. Campbell SE, Stone WL, Whaley SG, Qui M, and Krishnan K. Gamma tocopherol upregulates peroxisome proliferator activated receptor (PPAR) gamma expression in SW 480 human colon cancer cell lines. BMC Cancer 2003;3:25.
46. Rieusset J, Seydoux J, Anghel SI, Escher P, Michalik L, Tan NS, et al. Altered growth in male peroxisome proliferator activated receptor gamma Heterozygous mice: involvement of PPAR-gamma in a negative feedback regulation of growth hormone action. Mol. Endocrinol. 2004;18(10):2363-2377.
47. Graham BS. New approaches to vaccine adjuvants: Inhibiting the inhibitor. PLoS Med. 2006;3(1):e57.
48. Hara M, Tanaka K, and Hirota Y. Immune response to influenza vaccine in healthy adults and the elderly: Association with nutritional status. Vaccine 2005;23:1457-1463.
49. Rhodes J. Covalent chemical events in immune induction: Fundamental and therapeutic aspects. Immunol. Today 1996;17(9):436-441.
50. Soltysik S, Wu JY, Recchia J, Wheeler DA, Newman MJ, Coughlin RT, and Kensil CR. Structure/function studies of QS-21 adjuvant: Assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function. Vaccine 1995;13(15):1403-1410.
51. Rhodes J, Zheng B, and Lifely MR. Inhibition of specific T-cell activation by monosaccharides is through their reactivity as aldehydes. Immunology 1992;75:626-631.
52. Ara Y, Saito T, Takagi T, Hagiwara E, Miyagi Y, Sugiyama M, Kawamoto S, Ishii N, Yoshida T, Daisuke H, Koshino T, Okada H, and Okuda K. Zymosan enhances the immune response to DNA vaccine for human immunodeficiency virus type 1 through the activation of complement system. Immunology 2001;103:98-105.
53. Anada T, Okada N, Minari J, Karinaga R, Mizu M, Koumoto K, Shinkai S, and Sakurai K. CpG DNA/zymosan complex to enhance cytokine secretion owing to cocktail effect. Bioorg. Med. Chem. Lett . 2006;16:1301-1304.
54. Dong SF, Chen JM, Zhang W, Sun SH, Wang J, Gu JX, Boraschi D, and Qu D. Specific immune response to HBsAg is enhanced by beta-glucan oligosaccharide containing an alpha-(1-3)-linked bond and biased toward M2/Th2. Int. Immunol. 2007;7:725-733.
55. Boom WH. New TB vaccines: Is there a requirement for CD8+ T cells? J. Clin. Invest . 2007;117(8):2092-2094.
56. Braunstein M, Espinosa BJ, Chan J, Belisle JT, and Jacobs WR. SecA2 functions in the secretion of superoxide dismutase A in the virulence of Mycobacterium tuberculosis. Mol. Microbiol . 2003;48:453-464.
57. Tsumoto K, Ejima D, Kita Y, and Arakawa T. Why is arginine effective in suppressing aggregation? Protein Peptide Lett . 2005;12(7):613-619.
58. Roy S, Roy G, Mishra SC, and Prakash VR. Role of nitric oxide in central regulation of humoral immune response in rats. Indian J. Pharmacol. 2000;32:318-320.
59. Tayade C, Koti M, and Mishra SC. L-arginine stimulates intestinal intraepithelial lymphocyte functions and immune response in chickens orally immunized with live intermediate plus strain of infectious bursal disease vaccine. Vaccine 2006;24:5473-5480.
60. U.S. Patent No. 6001817. Pharmaceutical composition comprised of cisplatin, and processes for making and using same, 1999.
61. U.S. Patent No. 6562801. PPGPP and PPPGPP as immunomodulatory agents. Rombel R. Board of Regents, The University of Texas system, Austin, TX, 2003.
62. Bartz H, Mendoza Y, Gebker M, Fischborn T, Heeg K, and Dalpke A. Poly-guanosine strings improve cellular uptake and stimulatory activity of phosphodiester CpG oligonucleotides in human leukocytes. Vaccine 2004;23:148-155.
63. Lee J, Chuang TH, Redecke V, She L, Pitha PM, Carson DA, Raz E, and Cottam HB. Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: Activation of Toll-like-receptor 7. Proc. Natl. Acad. Sci . 2003;100(11):6646-6651.
64. Malliaros J, Quinn C, Arnold FH, Pearse MJ, Drane DP, Stewart TJ, and Macfarlan RI. Association of antigens to ISCOMATRIX adjuvant using metal chelation leads to improved CTL responses. Vaccine 2004;22:3968-3975.
65. Verheyden B, Andries K, and Rombaut B. Capsid and RNA stabilization of the oral polio vaccine. Vaccine 2001;19:1899-1905.
66. Wu R, Georgescu MM, Delpeyroux F, Guillot S, Balanant J, Simpson K, and Crainic R. Thermostabilization of live virus vaccines by heavy water. Vaccine 1995;13(12): 1058-1063.
67. Patent No. WO 2007/026180 assigned to Cambridge Biostability Ltd., Cambridge, GB, Improvements in the stabilization of biological materials, 2007.
68. Kalka-Moll WM, Tzianabos AO, Bryant PW, Niemeyer M, Ploegh HL, and Kasper DL. Zwitterionic polysaccharides stimulate T cells by MHC class II dependent interactions. J Immunol. 2002; 169:6149-6153.
69. Chackerian B, Lowy DR, and Schiller JT. Conjugation of a self-antigen to papillomaviruslike particles allows for efficient induction of protective autoantibodies. J. Clin. Invest . 2001;108(3):415-423.